Leaving the clinic on the same day

For most patients, the appointment follows a straightforward arc: arrive, receive the injection, and leave the same day. The procedure takes 30–45 minutes in an outpatient setting, with no general anaesthetic and no surgical incision. Under real-time ultrasound guidance, the collagen scaffold is placed directly into the cartilage defect, where it gels in situ within approximately 3–5 minutes — bonding to the defect base before the patient gets up from the treatment couch.

This brief setting window matters clinically. Although there is nothing the patient actively feels during those minutes, the scaffold is transitioning from a liquid to a stable gel, establishing the foundation that cells will later migrate into. The joint is kept undisturbed during this period to allow secure bonding.

Intravenous antibiotic prophylaxis is administered as part of the standard treatment package, reducing the risk of infection. This, alongside the six-week follow-up appointment that is scheduled at the time of treatment, signals that the pathway is actively monitored — not a single intervention followed by open-ended waiting.

Some localised soreness in the hours and days following the injection is to be expected. This reflects the body's natural inflammatory healing response rather than any tissue trauma comparable to surgery; in practice, patients typically describe it as manageable. The six-week clinic review marks the first formal clinical checkpoint, bridging the gap between the day of treatment and the structured recovery phases that follow.

Weeks 1–6: the Protect phase

The clinical term for the first four to six weeks after a large-joint ChondroFiller injection — 'Protect' — is deliberate. During this window, patients limit weight-bearing and restrict joint loading to controlled, gentle movement, avoiding both high-impact activities and the kind of repetitive, cyclical stress the joint would encounter during jogging or stair climbing at pace.

The rationale is mechanical, not precautionary convention. A 2024 biomechanical in-vitro study demonstrated that the collagen scaffold has initial instability under cyclic loading — it cannot yet fully shield the surrounding cartilage until stable defect filling is achieved. This means that even in the absence of significant pain, loading the joint too early carries a real structural risk. Low discomfort is not a reliable signal that the scaffold is ready for normal demands.

This is a common and understandable misconception worth pre-empting. Patients who feel relatively comfortable by week two or three may assume that activity can be increased accordingly. The biomechanical evidence suggests otherwise: the scaffold's mechanical maturation runs on a biological timeline that does not accelerate with low pain scores.

Soreness during this phase, when present, is a normal feature of healing in progress rather than a sign of complication; clinical experience consistently places it as qualitatively milder than the pain associated with open cartilage surgery. The six-week clinic review marks the formal close of the Protect phase and the entry point to a supervised rehabilitation programme.

What is happening biologically while you rest

Beneath the relative stillness of those first weeks, something measurably active is under way. A 2025 ex vivo study using a biomimetic osteochondral platform recorded a 2.4-fold increase in scaffold DNA content by day 14 — concrete evidence that progenitor-cell migration into the collagen matrix begins within the first two weeks. That figure reframes what 'rest' actually is: not inactivity, but the condition under which cell recruitment begins.

The mechanism driving this is acellular matrix-induced chondrogenesis. The ChondroFiller scaffold contains no donor cells; instead, it draws the patient's own progenitor cells in from the synovium and subchondral bone, which gradually mature into cartilage-forming chondrocytes over the following months. The scaffold supports the body's own repair processes rather than replacing them — a distinction that explains why protecting the joint during these early weeks is biologically consequential, not merely precautionary.

Post-treatment MRI studies provide a secondary window into this arc, documenting reduction in bone marrow oedema and diminished periarticular effusion in the weeks to months following injection. These are objective structural changes occurring in what might, from a patient's perspective, feel like an uneventful waiting period.

The early recovery, then, is quiet on the surface and active underneath.

How recovery timeline differs by joint

Recovery timelines vary meaningfully depending on which joint has been treated — and knowing this upfront prevents patients from benchmarking against someone else's experience.

For small-joint injections — into the wrist or a finger, for instance — the rest period is considerably shorter: typically one to two weeks before a return to light activity. These joints carry comparatively modest mechanical loads in daily life, and the scaffold stabilises in a less demanding environment.

Large-joint injections — knee and hip in particular — call for the full four-to-six week Protect phase. The difference is not a reflection of how technically involved the injection was or the size of the defect; it is simply a function of how much cyclical load these joints absorb in ordinary movement.

Rehabilitation schedules are therefore tailored to the treated joint. Patients with a wrist or finger injection should not assume the knee timeline applies to them, and vice versa.

From week 6: physiotherapy and returning to activity

Week 6 marks a genuine shift in the recovery arc. With the scaffold having had time to stabilise, a physiotherapist takes a more active role — introducing strengthening exercises to rebuild the muscle support around the joint and restore normal movement patterns under supervision.

During months 2–3, low-impact activities such as cycling and swimming are typically introduced. These are not arbitrary choices: they allow meaningful cardiovascular and muscular conditioning while keeping joint-loading forces within a range the maturing scaffold can tolerate. From roughly month 2 through to month 6, the emphasis progressively shifts to functional loading — jogging, balance work, and sport-specific drills are layered in as strength and confidence build.

Return to full sport is generally targeted from month 6 onwards, with some patients requiring the full 12 months depending on the joint treated, the size of the original defect, and individual progress. A prospective knee cohort of 17 patients (mean age 31) offers a useful reference point here: Lysholm and IKDC functional scores showed statistically significant improvement from baseline through to 6 months, but no significant further change between the 6- and 12-month assessments. In clinical terms, most functional benefit arrives within the first half-year — the plateau that follows is a sign of consolidation, not stagnation.

Over this same 1–2 year window, the collagen scaffold is gradually resorbed and replaced by the patient's own maturing tissue, completing the biological story that began in those quiet early weeks.

Factors that affect how recovery unfolds

Two pre-injection factors have the most bearing on how recovery actually unfolds in practice.

Baseline joint health. How much degenerative change was already present before treatment matters considerably. In hip studies, patients with advanced osteoarthritis — Tönnis grade 2 or 3 — have consistently shown poorer outcomes than those treated at earlier disease stages. ChondroFiller works by providing a scaffold for the patient's own progenitor cells; a joint already severely depleted of healthy surrounding tissue offers fewer of those cells to migrate in. Pre-treatment candidacy assessment — not just willingness to proceed — is therefore the first determinant of recovery quality.

Gel placement precision. During the injection, filling the defect level with the surrounding cartilage surface — rather than proud of it — is technically important. Overfilling is associated with fibrous tissue formation rather than the hyaline-like cartilage the scaffold is designed to support. Technique and imaging guidance both bear on this outcome, which is why clinical experience in cartilage applications is relevant to what the patient ultimately grows.

For the early weeks specifically, the finer details of recovery — swelling management, whether a walking aid is needed, precise activity restrictions for days one through fourteen — vary by joint, defect characteristics, and individual baseline function. Current protocols are drawn largely from the broader ChondroFiller literature and adapted to each patient's circumstances at the point of assessment. The treating clinician is the right person to set those specifics. For patients considering whether ChondroFiller is the right pathway, a specialist assessment at London Cartilage Clinic can answer that question at londoncartilage.com.

1. [1] Influence of Cartilage Defects and a Collagen Gel on Integrity of Corresponding Intact Cartilage: A Biomechanical In-Vitro Study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Controlled, Randomized Multicenter Study: ChondroFiller Liquid vs Microfracturing for Focal Cartilage Defects of the Knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Cartilage Reconstruction Using ChondroFiller in Intra-Articular Distal Radius Fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936